LIVIVO - Search results -

Search results

Result 1 - 10 of total 87

Search options

Article ; Online: Studies on Ergothioneine. IX. Ergothioneine Stimulates Mouse Spermatozoa and Fertilization in vitro: (ergothioneine/fertilization/acrosome reaction/sperm penetration).

Mayumi, Tadanori / Kawano, Hiroko / Kawai, Yuichi / Hama, Takao

2023 Volume 26, Issue 6, Page(s) 563–569

Abstract: The effects of ergothioneine on spermatozoa and ova were investigated in vitro and in vivo. Spermatozoa were treated with ergothioneine in vitro, and injected into the uterine cavity of female mice immediately after the induction of superovulation. The ... ...

Abstract	The effects of ergothioneine on spermatozoa and ova were investigated in vitro and in vivo. Spermatozoa were treated with ergothioneine in vitro, and injected into the uterine cavity of female mice immediately after the induction of superovulation. The ova were recovered 24 hr later and assessed for fertilization. Preincubation of spermatozoa with ergothioneine resulted in a significant increase in the fertilization rate. When ova were inseminated in the same manner in vitro with spermatozoa treated with 0.1 or 1.0 mM of ergothioneine, the penetration rate was significantly increased. These results suggest that ergothioneine is effective in inducing both capacitation and the acrosome reaction of mouse spermatozoa. Ergothioneine at concentrations of 0.1 and 1.0 mM in the preincubation medium was also effective in inducing the acrosome reaction of guinea pig spermatozoa. However, it had no significant effect on the development of 2-cell ova in vitro.
Language	English
Publishing date	2023-06-06
Publishing country	Japan
Document type	Journal Article
ZDB-ID	280433-5
ISSN	1440-169X ; 0012-1592
ISSN (online)	1440-169X
ISSN	0012-1592
DOI	10.1111/j.1440-169X.1984.00563.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 194: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: [DDS and Me].

Mayumi, Tadanori

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

2004 Volume 124, Issue 7, Page(s) 397–415

Abstract: With the success of the human genome project, the focus of life science research has shifted to the functional and structural analyses of proteins, such as proteomics and structural genomics. These analyses of proteins including newly identified proteins ...

Abstract	With the success of the human genome project, the focus of life science research has shifted to the functional and structural analyses of proteins, such as proteomics and structural genomics. These analyses of proteins including newly identified proteins are expected to contribute to the identification of therapeutically applicable proteins for various diseases. Thus, pharmaco-proteomic-based drug discovery and development for protein therapies, including gene therapy, cell therapy, and vaccine therapy, is attracting current attention. However, there is clinical difficulty in using almost all bioactive proteins, because of their very low stability and pleiotropic actions in vivo. To promote pharmaco-proteomic-based drug discovery and development, we have attempted to develop drug delivery systems (DDSs), such as the protein-drug innovation system and the optimal cell therapeutic system. In this review, we introduce our original DDSs.
MeSH term(s)	Animals ; Cell- and Tissue-Based Therapy ; Directed Molecular Evolution ; Drug Delivery Systems ; Genetic Therapy ; Humans ; Nanotechnology ; Proteomics ; Vaccines
Chemical Substances	Vaccines
Language	Japanese
Publishing date	2004-06-14
Publishing country	Japan
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	200514-1
ISSN	1347-5231 ; 0031-6903 ; 0372-7750 ; 0919-2085 ; 0919-2131
ISSN (online)	1347-5231
ISSN	0031-6903 ; 0372-7750 ; 0919-2085 ; 0919-2131
DOI	10.1248/yakushi.124.397
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 643: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Development of novel technology of DDS for gene therapy.

Nakagawa, Shinsaku / Mayumi, Tadanori

Drug metabolism and pharmacokinetics

2004 Volume 18, Issue 4, Page(s) 223–229

Abstract: In the near future, not only "systemic pharmacokinetics" but also "intracellular pharmacokinetics" seems to be important in Drug Delivery System (DDS) research for gene therapy. Beyond the basic philosophy of DDS of "delivering the optimal amounts of ... ...

Abstract	In the near future, not only "systemic pharmacokinetics" but also "intracellular pharmacokinetics" seems to be important in Drug Delivery System (DDS) research for gene therapy. Beyond the basic philosophy of DDS of "delivering the optimal amounts of drugs to a target site", it is now necessary to "express the gene (as a drug) efficiently in a target cell for a required period" in gene therapy. To achieve these objectives, vectors for introducing the gene into the target cell are being improved, and techniques to efficiently express the transgene and to regulate the transgene expression are being developed. DDS is expected to play a large part in achieving this goal. Here, we review a novel DDS technology to satisfy these criteria.
Language	English
Publishing date	2004-12-15
Publishing country	England
Document type	Journal Article
ZDB-ID	2095748-8
ISSN	1347-4367 ; 0916-1139
ISSN	1347-4367 ; 0916-1139
DOI	10.2133/dmpk.18.223
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3734: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: [Creation of functional muteins using phage display system results in a novel PEGylation system].

Tsutsumi, Yasuo / Mayumi, Tadanori

Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme

2003 Volume 48, Issue 11 Suppl, Page(s) 1519–1526

MeSH term(s)	Drug Delivery Systems ; Drug Design ; Humans ; Macromolecular Substances ; Peptide Library ; Polyethylene Glycols ; Protein Binding ; Proteins ; Proteome ; Tumor Necrosis Factor-alpha
Chemical Substances	Macromolecular Substances ; Peptide Library ; Proteins ; Proteome ; Tumor Necrosis Factor-alpha ; Polyethylene Glycols (30IQX730WE)
Language	Japanese
Publishing date	2003-08
Publishing country	Japan
Document type	Journal Article ; Review
ZDB-ID	391163-9
ISSN	0039-9450
ISSN	0039-9450
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 637: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immune cell recruitment and cell-based system for cancer therapy.

Gao, Jian-Qing / Okada, Naoki / Mayumi, Tadanori / Nakagawa, Shinsaku

Pharmaceutical research

2008 Volume 25, Issue 4, Page(s) 752–768

Abstract: Immune cells, such as cytotoxic T lymphocytes, natural killer cells, B cells, and dendritic cells, have a central role in cancer immunotherapy. Conventional studies of cancer immunotherapy have focused mainly on the search for an efficient means to prime/ ...

Abstract	Immune cells, such as cytotoxic T lymphocytes, natural killer cells, B cells, and dendritic cells, have a central role in cancer immunotherapy. Conventional studies of cancer immunotherapy have focused mainly on the search for an efficient means to prime/activate tumor-associated antigen-specific immunity. A systematic understanding of the molecular basis of the trafficking and biodistribution of immune cells, however, is important for the development of more efficacious cancer immunotherapies. It is well established that the basis and premise of immunotherapy is the accumulation of effective immune cells in tumor tissues. Therefore, it is crucial to control the distribution of immune cells to optimize cancer immunotherapy. Recent characterization of various chemokines and chemokine receptors in the immune system has increased our knowledge of the regulatory mechanisms of the immune response and tolerance based on immune cell localization. Here, we review the immune cell recruitment and cell-based systems that can potentially control the systemic pharmacokinetics of immune cells and, in particular, focus on cell migrating molecules, i.e., chemokines, and their receptors, and their use in cancer immunotherapy.
MeSH term(s)	Adoptive Transfer/adverse effects ; Animals ; Chemokines/genetics ; Chemokines/metabolism ; Chemotaxis ; Dendritic Cells/immunology ; Dendritic Cells/transplantation ; Genetic Therapy/adverse effects ; Genetic Vectors ; Humans ; Immunity, Cellular ; Immunotherapy/adverse effects ; Immunotherapy/methods ; Immunotherapy/trends ; Neoplasm Metastasis ; Neoplasms/genetics ; Neoplasms/immunology ; Neoplasms/pathology ; Neoplasms/therapy ; Neovascularization, Pathologic/immunology ; Receptors, Chemokine/metabolism ; Treatment Outcome
Chemical Substances	Chemokines ; Receptors, Chemokine
Language	English
Publishing date	2008-04
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	843063-9
ISSN	1573-904X ; 0724-8741 ; 0739-0742
ISSN (online)	1573-904X
ISSN	0724-8741 ; 0739-0742
DOI	10.1007/s11095-007-9443-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1937: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Development of novel drug delivery system (DDS) technologies for proteomic-based drug development.

Shibata, Hiroko / Nakagawa, Shinsaku / Mayumi, Tadanori / Tsutsumi, Yasuo

Biological & pharmaceutical bulletin

2004 Volume 27, Issue 10, Page(s) 1483–1488

Abstract: With the success of human genome projects, the focus of life science research has shifted to the functional and structural analyses of proteins, such as disease proteomics. These structural and functional analyses of expressed proteins in the cells and/ ... ...

Abstract	With the success of human genome projects, the focus of life science research has shifted to the functional and structural analyses of proteins, such as disease proteomics. These structural and functional analyses of expressed proteins in the cells and/or tissues are expected to contribute to the identification of therapeutically applicable proteins for various diseases. Thus, pharmaco-proteomic based drug development for protein therapies is most noticed currently. However, there is a clinical difficulty to use almost bioactive proteins, because of their very low stability and pleiotropic actions in vivo. To promote pharmaco-proteomic based drug development for protein therapies to various diseases, we have attempted to establish a system for creating functional mutant proteins (muteins) with desired properties, and to develop a site-specific polymer-conjugation system for further improving the therapeutic potency of proteins. In this review, we are introducing our original protein-drug innovation systems mentioned above.
MeSH term(s)	Animals ; Drug Delivery Systems/methods ; Drug Design ; Proteomics
Language	English
Publishing date	2004-10
Publishing country	Japan
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1150271-x
ISSN	1347-5215 ; 0918-6158
ISSN (online)	1347-5215
ISSN	0918-6158
DOI	10.1248/bpb.27.1483
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1474: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [PPARgamma-gene therapy using an adenovirus vector for inflammatory bowel disease].

Nakajima, Atsushi / Katayama, Kazufumi / Mayumi, Tadanori

Nihon yakurigaku zasshi. Folia pharmacologica Japonica

2003 Volume 122, Issue 4, Page(s) 309–316

Abstract: Peroxisome proliferator-activated receptor gamma (PPARgamma) is one of the nuclear receptors that plays a central role in adipocyte differentiation and insulin sensitivity. Recently, PPARgamma has also been recognized as a suppressive regulator of ... ...

Abstract	Peroxisome proliferator-activated receptor gamma (PPARgamma) is one of the nuclear receptors that plays a central role in adipocyte differentiation and insulin sensitivity. Recently, PPARgamma has also been recognized as a suppressive regulator of inflammation in the gastrointestinal tract. We summarize here the therapeutic benefits of PPARgamma-gene therapy using a replication-deficient adenovirus vector expressing PPARgamma (AdRGD-PPARgamma). We demonstrate that PPARgamma- protein levels are decreased in dextran sodium sulfate-induced colitis and restored in this model by intraperitoneal administration of the AdRGD-PPARgamma. Treatment with AdRGD-PPARgamma and PPARgamma-specific ligands resulted in a marked amelioration of tissue inflammation associated with the colitis, including reduction in intercellular adhesion molecule-1, cyclooxygenase-2, and tumor necrosis factor-alpha expression. Our results suggest that gene delivery of PPARgamma may open up a novel therapeutic approach for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.
MeSH term(s)	Adenoviridae/genetics ; Animals ; Colitis/therapy ; Genetic Therapy/methods ; Genetic Vectors ; Inflammatory Bowel Diseases/therapy ; Mice ; Receptors, Cytoplasmic and Nuclear/genetics ; Transcription Factors/genetics
Chemical Substances	Receptors, Cytoplasmic and Nuclear ; Transcription Factors
Language	Japanese
Publishing date	2003-09-01
Publishing country	Japan
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	1097532-9
ISSN	1347-8397 ; 0015-5691
ISSN (online)	1347-8397
ISSN	0015-5691
DOI	10.1254/fpj.122.309
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 439: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach.

Yoshioka, Yasuo / Tsutsumi, Yasuo / Nakagawa, Shinsaku / Mayumi, Tadanori

Current vascular pharmacology

2003 Volume 2, Issue 3, Page(s) 259–270

Abstract: Tumor targeting therapy, that is "Missile therapy", using a complex composed of a tumor suppressive drug and a whole antibody against tumor cells, is expected to become an attractive chemotherapy strategy. However, clinically convincing results have not ... ...

Abstract	Tumor targeting therapy, that is "Missile therapy", using a complex composed of a tumor suppressive drug and a whole antibody against tumor cells, is expected to become an attractive chemotherapy strategy. However, clinically convincing results have not yet been obtained mainly due to poor transport from the circulation to tumor tissue and marked toxicity. Recently, recombinant immunotoxins, composed of an Fv fragment of an antibody to a tumor-related antigen fused to various truncated toxins have been developed to overcome the distribution of immunotoxins in tumors. These recombinant immunotoxins have shown encouraging clinical results for some hematopoietic malignancies. However, there were no significant anti-tumor responses to many tumors, especially solid tumors, probably due to their rapid clearance from the circulation and their immunogenicity and antigenicity. More recently, PEGylation of recombinant immunotoxins has been attempted to overcome these drawbacks. It was found that PEGylation of recombinant immunotoxins improves their effectiveness. We discuss the recent progress in tumor missile therapy. In contrast to others, we developed "Missile therapy against tumor blood vessels" by using specific monoclonal antibodies against tumor endothelial cells rather than actual tumor cells. The complex between antibodies to tumor vascular endothelial cells and anti-tumor drugs can freely access the target cells without concern for their vascular permeability. These preparations have exhibited excellent anti-tumor effects for solid tumors. In this review, we also discuss this vascular targeting therapy as an attractive new strategy for tumor chemotherapy.
MeSH term(s)	Animals ; Antibodies, Monoclonal/therapeutic use ; Endothelial Cells/physiology ; Humans ; Immunoconjugates/therapeutic use ; Immunotoxins/therapeutic use ; Interleukin-6/therapeutic use ; Neoplasms/blood supply ; Neoplasms/therapy ; Polyethylene Glycols/therapeutic use ; Recombinant Proteins/therapeutic use ; Zinostatin/administration & dosage
Chemical Substances	Antibodies, Monoclonal ; Immunoconjugates ; Immunotoxins ; Interleukin-6 ; Recombinant Proteins ; Polyethylene Glycols (3WJQ0SDW1A) ; Zinostatin (9014-02-2)
Language	English
Publishing date	2003-12-15
Publishing country	United Arab Emirates
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2192362-0
ISSN	1570-1611
ISSN	1570-1611
DOI	10.2174/1570161043385682
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6282: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Molecular design of bioconjugated cell adhesion peptide with a water-soluble polymeric modifier for enhancement of antimetastatic effect.

Yamamoto, Yoko / Tsutsumi, Yasuo / Mayumi, Tadanori

Current drug targets

2002 Volume 3, Issue 2, Page(s) 123–130

Abstract: The adhesive interaction of tumor cells with various components of the extracellular matrix (ECM), such as laminin and fibronectin appears to play a crucial role in tumor metastasis. It has been reported that adhesive peptides, such as Tyr-Ile-Gly-Ser- ... ...

Abstract	The adhesive interaction of tumor cells with various components of the extracellular matrix (ECM), such as laminin and fibronectin appears to play a crucial role in tumor metastasis. It has been reported that adhesive peptides, such as Tyr-Ile-Gly-Ser-Arg (YIGSR) in laminin and Arg-Gly-Asp (RGD), inhibited adhesion and invasion of various tumor cells to ECM in vitro, and exhibited inhibitory effects on pulmonary metastasis of B16-BL6 melanoma cells in mice. However, large doses of these peptides were required for significant anti-metastatic effects in vivo, probably due to their rapid degradation by various peptidases and their rapid excretion from the blood into the urine. To overcome these problems, the development of an appropriate drug delivery system (DDS) is required to improve in vivo stability and prolong plasma half-lives. Several strategies such as peptide-cyclization and D-amino acid substation have been reported to improve stability in blood by inhibiting enzymatic degradation. However, even these approaches have proven insufficient to overcome rapid renal clearance from the circulation. On the other hand, bioconjugation with water-soluble polymeric modifiers could markedly prolong the plasma half-lives by not only increasing peptidase resistance but also impeding renal excretion. In addition, it is possible to strictly control the in vivo pharmacokinetics of a peptide by introducing functional molecules with targeting or slow release capacities to the polymeric modifier. In this review we demonstrate with reference to our recent studies that bioconjugation of adhesive peptides with the appropriate polymeric modifier can enhance antimetastatic activity and may facilitate therapeutic use.
MeSH term(s)	Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Adhesion Molecules/administration & dosage ; Cell Adhesion Molecules/chemical synthesis ; Cell Adhesion Molecules/chemistry ; Drug Delivery Systems/methods ; Humans ; Neoplasm Metastasis/prevention & control ; Peptide Biosynthesis ; Polymers/administration & dosage ; Polymers/chemical synthesis ; Polymers/chemistry ; Solubility ; Water/chemistry
Chemical Substances	Antineoplastic Agents ; Cell Adhesion Molecules ; Polymers ; Water (059QF0KO0R)
Language	English
Publishing date	2002-04
Publishing country	United Arab Emirates
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2064859-5
ISSN	1873-5592 ; 1389-4501
ISSN (online)	1873-5592
ISSN	1389-4501
DOI	10.2174/1389450024605427
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5578: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Nuclear receptors as targets for drug development: the role of nuclear receptors during neural stem cell proliferation and differentiation.

Katayama, Kazufumi / Wada, Koichiro / Nakajima, Atsushi / Kamisaki, Yoshinori / Mayumi, Tadanori

Journal of pharmacological sciences

2005 Volume 97, Issue 2, Page(s) 171–176

Abstract: The fate of stem cells, such as neural stem cells and hematopoietic stem cells, depends on strictly regulated signaling events including activation of nuclear receptors, resulting in subsequent gene induction. Recently, we demonstrated that PPARgamma, a ... ...

Abstract	The fate of stem cells, such as neural stem cells and hematopoietic stem cells, depends on strictly regulated signaling events including activation of nuclear receptors, resulting in subsequent gene induction. Recently, we demonstrated that PPARgamma, a ligand-activated nuclear receptor, plays an important role in regulating the proliferation and differentiation of murine neural stem cell (NSC). NSC prepared from heterozygous PPARgamma-deficient mouse exhibited a slower growth rate compared with that of wild-type mouse, which was also demonstrated in PPARgamma-knockdown NSC that was generated by the lentiviral-vector-mediated RNA interference approach. These studies have important implications for understanding central nervous system functions and developing a therapy for neurodegenerative disorders. In this review, recent findings on stem cell biology, especially focusing on nuclear receptors in NSCs, including our current study, will be discussed.
MeSH term(s)	Animals ; Cell Differentiation/drug effects ; Cell Differentiation/physiology ; Cell Proliferation/drug effects ; Drug Delivery Systems/methods ; Humans ; Neurons/cytology ; Neurons/drug effects ; Neurons/physiology ; Pharmaceutical Preparations/administration & dosage ; Pharmaceutical Preparations/metabolism ; Receptors, Cytoplasmic and Nuclear/physiology ; Stem Cells/cytology ; Stem Cells/drug effects ; Stem Cells/physiology
Chemical Substances	Pharmaceutical Preparations ; Receptors, Cytoplasmic and Nuclear
Language	English
Publishing date	2005-02-11
Publishing country	Japan
Document type	Journal Article ; Review
ZDB-ID	2104264-0
ISSN	1347-8648 ; 1347-8613
ISSN (online)	1347-8648
ISSN	1347-8613
DOI	10.1254/jphs.fmj04008x3
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 237: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito